Colo-rectal CancerMETRADNCT07000474
Multiparametric Characterization of Colorectal Cancers (METRAD)
An observational study of Colo-rectal Cancer, run by University Hospital, Brest at 1 site in France.
Trial summary
The primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, CT scans, and molecular analysis. This analysis will be conducted on a retrospective cohort recruited at CHU Brest (training group). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colo-rectal Cancer
- What is being tested?
- Omics
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 1 Mar 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of patients diagnosed with colorectal cancer (CRC) who are undergoing various stages of treatment and care. The cohort includes individuals who have been surgically treated for colorectal cancer, with or without additional therapies such as chemotherapy, radiotherapy, or immunotherapy. The population may also include patients who have undergone routine follow-up care after treatment.
Who may be able to join
- Patients who have undergone surgery for colorectal cancer.
Who cannot join
- Patients under legal protection (guardianship, curatorship, etc.)
- Refusal to participate (expressed opposition)
- Individuals with conditions that could interfere with the study protocol or impact data integrity
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Multiparametric Characterization of Colorectal Cancers
The primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, CT scans, and molecular analysis. This analysis will be conducted on a retrospective cohort recruited at CHU Brest (training group). The model will then be validated using external cohorts from other centers (test group).
Read the detailed description
Around 20% of patients with colorectal cancer present with synchronous liver metastases at the time of diagnosis. In recent years, there has been increasing interest in the high-throughput extraction of quantitative data from medical images, a technique known as radiomics. Radiomic analysis can involve both qualitative and quantitative imaging parameters, which may be used independently or integrated into multiparametric prediction models.
This is a multicenter, retrospective study designed to investigate the demographic, clinical, and radiological features, treatment regimens, and outcomes of patients diagnosed with colorectal cancer. The study will involve the collection of anonymized clinical data, including age, sex, diagnosis date, treatment details, results from histopathological and genetic analyses, as well as pre- and post-treatment medical imaging typically performed as part of the management of colorectal cancer patients, along with survival and tumor recurrence data.
PRIMARY EVALUATION CRITERIA Prediction of recurrence/treatment response based on the radiomic model.
SECONDARY EVALUATION CRITERIA The impact of CT scan image acquisition and reconstruction parameters on the prognostic model.
- Conditions
- Colo-rectal Cancer
- Being tested
- Omics
- Keywords
- colon cancer, rectal cancer, radiomics
- Medical subject headings
- Colonic Neoplasms, Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OmicsOther
Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
| Study group | Role | What they receive |
|---|---|---|
| Brest | Training cohort Receives: Other: Omics | |
| External | Validation cohort Receives: Other: Omics |
What is being measured
The primary outcome is the main question the study is designed to answer.
survival predictive model
The primary objective is to evaluate the predictive value of a model built through multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2025
- Study start1 Mar 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colo-rectal CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07000474
- Sponsor's protocol ID
- 29BRC24.0393 - METRAD
- Acronym
- METRAD
- Status last verified
- Mar 2025
- First submitted
- 20 May 2025
- Last updated
- 3 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiparametric Characterization of Colorectal Cancers
- ClinicalTrials.gov ID
- NCT07000474
- Acronym / sponsor ID
- METRAD / 29BRC24.0393 - METRAD
- Conditions
- Colo-rectal Cancer
- Keywords
- colon cancer, rectal cancer, radiomics
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, CT scans, and molecular analysis. This analysis will be conducted on a retrospective cohort recruited at CHU Brest (training group). The model will then be validated using external cohorts from other centers (test group).
Detailed description
Around 20% of patients with colorectal cancer present with synchronous liver metastases at the time of diagnosis. In recent years, there has been increasing interest in the high-throughput extraction of quantitative data from medical images, a technique known as radiomics. Radiomic analysis can involve both qualitative and quantitative imaging parameters, which may be used independently or integrated into multiparametric prediction models.
This is a multicenter, retrospective study designed to investigate the demographic, clinical, and radiological features, treatment regimens, and outcomes of patients diagnosed with colorectal cancer. The study will involve the collection of anonymized clinical data, including age, sex, diagnosis date, treatment details, results from histopathological and genetic analyses, as well as pre- and post-treatment medical imaging typically performed as part of the management of colorectal cancer patients, along with survival and tumor recurrence data.
PRIMARY EVALUATION CRITERIA Prediction of recurrence/treatment response based on the radiomic model.
SECONDARY EVALUATION CRITERIA The impact of CT scan image acquisition and reconstruction parameters on the prognostic model.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Brest | – | Other: OmicsTraining cohort |
| External | – | Other: OmicsValidation cohort |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of patients diagnosed with colorectal cancer (CRC) who are undergoing various stages of treatment and care. The cohort includes individuals who have been surgically treated for colorectal cancer, with or without additional therapies such as chemotherapy, radiotherapy, or immunotherapy. The population may also include patients who have undergone routine follow-up care after treatment.
Key inclusion criteria (1 listed)
- Patients who have undergone surgery for colorectal cancer.
Key exclusion criteria (3 listed)
- Patients under legal protection (guardianship, curatorship, etc.)
- Refusal to participate (expressed opposition)
- Individuals with conditions that could interfere with the study protocol or impact data integrity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OmicsMultiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis. | Other | Brest, External |
Primary outcome
survival predictive model
Time frame: 2 years
The primary objective is to evaluate the predictive value of a model built through multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2025.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Related trials for Colo-rectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colo-rectal Cancer, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
survival predictive model (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025.